← Back to all signals
RESEARCH PAPER ANALYSIS

Evaluation of Orthostatic Hypotension in Patients With Idiopathic Parkinson's Disease Utilizing the Head-Up Tilt Test.

Prospective, single-center study of 114 idiopathic PD patients found orthostatic hypotension in 28% (detected by head-up tilt testing), with prevalence rising sharply with disease duration and Hoehn & Yahr stage and including asymptomatic cases.

PMID41913885
JournalCureus
Publication Date2026-02-01
Ingested2026-04-28 08:58 PM
EXECUTIVE SUMMARY

What the AI sees

Prospective, single-center study of 114 idiopathic PD patients found orthostatic hypotension in 28% (detected by head-up tilt testing), with prevalence rising sharply with disease duration and Hoehn & Yahr stage and including asymptomatic cases.

WHY IT MATTERS

Research significance

The paper has moderate translational value: it supports routine HUTT screening to prevent falls and to stratify or monitor patients for symptomatic autonomic therapies and clinical trials, but offers limited mechanistic or novel therapeutic-target insights for disease-modifying drug discovery.

ABSTRACT

Source abstract

INTRODUCTION: Parkinson's disease (PD) is a neurodegenerative disorder, affecting individuals aged 60 and older, with rapidly increasing prevalence in aging populations, particularly in India. Apart from classical motor symptoms, nonmotor symptoms, particularly orthostatic hypotension (OH), significantly affect the quality of life, increasing the fall risk that contributes to increasing morbidity and mortality. This single-center, prospective, cross-sectional observational study evaluates OH, a key cardiovascular autonomic dysfunction, in idiopathic PD patients using the head-up tilt test (HUTT) to assess its prevalence and correlation with disease duration and severity. Conducted from July 2023 to June 2024 at the Department of Neurology, Indira Gandhi Government General Hospital and Post Graduate Institute, Puducherry, India, the study enrolled 114 patients diagnosed according to UK Brain Bank criteria, excluding confounders such as diabetic neuropathy or cardiovascular comorbidities. METHODS: Patients underwent detailed clinical evaluation, demographics, PD duration, autonomic symptom history, and Modified Hoehn and Yahr staging, and the HUTT was commenced at 60° after 30 minutes of supine rest. Systolic blood pressure (SBP), diastolic blood pressure (DBP), mean arterial pressure, and heart rate were obtained every five minutes before tilt; one, three, and five minutes during tilt; and one minute after tilt, as indicated for patient safety. OH was defined as a drop in SBP ≥20 mmHg and/or DBP ≥10 mmHg within three to five minutes. Data analysis used Statistical Package for the Social Sciences version 20 (IBM Corp., Armonk, NY) with chi-square test, analysis of variance, t tests, and Pearson correlation (p < 0.05 significant). Ethical approval was obtained from the institution's ethics committee, and informed consent was obtained to ensure confidentiality. RESULTS: The mean age was 65 ± 11.19 years, 62.28% were male, and the mean disease duration was 2.75 ± 1.93 years. OH prevalence was 28% (32/114 patients). No gender association was observed (p = 0.180), but strong links with duration (p < 0.00001; 0% in less than one year, 100% in greater than five years) and H&Y stage (p < 0.00001; 7.4% stage 1, 100% stage 3) were noticed. Disease duration positively correlated with H&Y stage (r = 0.459, p = 0.0001). DISCUSSION: OH increases progressively with PD duration and motor severity, reflecting autonomic neurodegeneration independent of dopaminergic loss, consistent with prior studies. The HUTT's sensitivity detected asymptomatic cases, which are vital for fall mitigation. HUTT proved superior to static measures for early detection. Limitations of the study include a single-center design and the absence of a control group. Routine screening via HUTT is recommended for advanced PD to prevent falls/syncope via interventions (e.g., hydration and midodrine). CONCLUSION: OH affects 28% of idiopathic PD patients, strongly tied to duration and H&Y stage; HUTT enables proactive management to enhance the quality of life.

SUPPORTING PAPER SET

32 more papers to review

Ranked by current scoring engine
1 The cGAS-STING-Glymphatic-gut Axis in Parkinson's disease: A proposed self-amplifying triad of Neuroinflammation and therapeutic opportunity. International immunopharmacology 91.0 2 Immunosenescence and Inflammaging as Drivers of Neurodegeneration: Cellular Mechanisms, Neuroimmune Crosstalk, and Therapeutic Implications. Cells 91.0 3 Flavonoids improve neurotransmitters for Parkinson's treatment: mechanism and therapeutic potential. Frontiers in pharmacology 88.0 4 Alpha-Lipoic Acid and Biotin in Neurodegenerative Diseases: Convergent Mechanistic Insights from Preclinical Models to Clinical Perspectives. Neurology international 78.0 5 The Gut Microbiota in Parkinson's Disease: Mechanistic Insights into Microbial-Host Interactions. Microorganisms 85.0 6 Linking inflammation, metabolic dysfunction, and neurodegeneration: a comprehensive review of TLR2 pathways in type 2 diabetes. Frontiers in clinical diabetes and healthcare 80.0 7 Neuroprotective effects of GLP-2 and a GLP-2/GIP dual receptor agonist in an MPTP-induced mouse model of Parkinson's disease. Peptides 86.0 8 TNF alpha unmasks enteric malate aspartate shuttle dysfunction bridging Parkinson disease and intestinal inflammation. Nature communications 91.5 9 Lipid Metabolism and Neurodegeneration: Mechanistic Insights and Therapeutic Targets. Ageing research reviews 82.0 10 Shared functional microbiome signatures in Parkinson's disease and constipation predominate irritable bowel syndrome despite taxonomic divergence. Brain, behavior, & immunity - health 80.0 11 Benzimidazole as a Versatile Scaffold for Developing Neurotherapeutics Against Neurodegenerative Diseases. ChemMedChem 74.0 12 Biomimicking neuromelanin reverses the gait deficits and dopaminergic neuronal loss in the Parkinson's disease. Colloids and surfaces. B, Biointerfaces 86.0 13 Neuroprotective roles of klotho: Molecular pathways and therapeutic implications for cognitive health in neurological and psychiatric diseases. Experimental physiology 84.0 14 Flavonoid Rutin Reduces Intestinal Inflammation in an Experimental Model of Parkinson's Disease. Neurotoxicity research 70.0 15 Nanostructured Lipid Carriers Enhance Brain Delivery and Antioxidant Efficacy of a Small-Molecule MAO B Inhibitor for Neurodegenerative Disease Therapy. Molecular pharmaceutics 78.0 16 Pathophysiological Role of the Gut Brain Axis in Parkinson's Disease: From Microbial Metabolites and Intestinal Permeability to Central Neuroinflammation. Current neurovascular research 86.0 17 Parkinson's Disease: From Metabolism to Genetics-A Comprehensive Review. Current issues in molecular biology 86.0 18 Navigating the cholesterol maze: Key insights on use of statins in neurodegenerative disorders. Neuroprotection (Chichester, England) 76.0 19 Integrative network pharmacology delineates dual GPCR and non-GPCR mechanisms of blended and individual Taikong Blue lavender and Pingyin rose essential oils in neurodegenerative and psychiatric disorders. Computers in biology and medicine 65.0 20 Models of neuroprotection in Parkinson's disease: Exploring cellular, molecular, and microenvironmental targets. Experimental neurology 78.0 21 Hyaluronic acid: emerging roles and biomaterial innovations in Alzheimer's and Parkinson's disease therapy. Frontiers in pharmacology 75.2 22 Molecular mechanisms underlying Parkinson's disease and role of phytochemicals, α-synuclein, sirtuins, and incretin mimetics in potential therapy. Frontiers in pharmacology 75.0 23 Lipid droplets in neurodegenerative diseases: pathological drivers and therapeutic vulnerabilities. Cell death discovery 82.0 24 Brain-gut-microbiota axis: a review on the bidirectional regulatory mechanisms between gut microbiota and brain and their disease interactions. Frontiers in microbiology 74.0 25 Long non-coding RNAs in neurodegenerative diseases - Molecular mechanisms, liquid biopsy biomarkers, and therapeutic targets: A review. Biomolecules & biomedicine 84.0 26 Neurosyphilis and Parkinsonism: Overlapping Pathophysiology and Emerging Therapeutic Insights. Current neurovascular research 76.0 27 Molecular biochemistry of soluble epoxide hydrolase in lipid mediator pathways and neuroinflammatory responses. The Journal of steroid biochemistry and molecular biology 82.0 28 Multifaceted role of CNPY2 beyond ER stress: Disease implications and therapeutic potential. Cell stress 83.3 29 Neuroprotective Role of Exercise-based Physiotherapy Combined with Pharmacological Agents in Parkinson's Disease. Central nervous system agents in medicinal chemistry 64.0 30 Distinct metabolomic and proteomic signatures in Parkinson's disease patients with REM sleep behavior disorder. Signal transduction and targeted therapy 84.0 31 HMGB1-mediated neuroinflammation: molecular mechanisms and emerging therapeutic approaches. Inflammopharmacology 78.0 32 Beyond acid-base dyshomeostasis: Dynamic instability of neuronal lysosomal pH as a pathogenic mechanism and therapeutic target in neurological diseases. Biochemical pharmacology 88.0
Neurocompute Parkinson’s Narrative Velocity Infographic
NEUROCOMPUTE VISUAL SYSTEM

Open the Narrative Velocity Map

Explore the full Parkinson’s research intelligence diagram.

Expand Intelligence View →
Full Neurocompute Infographic